JP2010526807A5 - - Google Patents

Download PDF

Info

Publication number
JP2010526807A5
JP2010526807A5 JP2010507419A JP2010507419A JP2010526807A5 JP 2010526807 A5 JP2010526807 A5 JP 2010526807A5 JP 2010507419 A JP2010507419 A JP 2010507419A JP 2010507419 A JP2010507419 A JP 2010507419A JP 2010526807 A5 JP2010526807 A5 JP 2010526807A5
Authority
JP
Japan
Prior art keywords
alkyl
group
substituted
halogens
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010507419A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010526807A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/005726 external-priority patent/WO2008137105A1/en
Publication of JP2010526807A publication Critical patent/JP2010526807A/ja
Publication of JP2010526807A5 publication Critical patent/JP2010526807A5/ja
Pending legal-status Critical Current

Links

JP2010507419A 2007-05-07 2008-05-02 抗糖尿病活性を有する縮合芳香族化合物を用いた治療法 Pending JP2010526807A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92794907P 2007-05-07 2007-05-07
PCT/US2008/005726 WO2008137105A1 (en) 2007-05-07 2008-05-02 Method of treatment using fused aromatic compounds having anti-diabetic activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014002247A Division JP2014088424A (ja) 2007-05-07 2014-01-09 抗糖尿病活性を有する縮合芳香族化合物を用いた治療法

Publications (2)

Publication Number Publication Date
JP2010526807A JP2010526807A (ja) 2010-08-05
JP2010526807A5 true JP2010526807A5 (enExample) 2011-05-26

Family

ID=39943845

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010507419A Pending JP2010526807A (ja) 2007-05-07 2008-05-02 抗糖尿病活性を有する縮合芳香族化合物を用いた治療法
JP2014002247A Pending JP2014088424A (ja) 2007-05-07 2014-01-09 抗糖尿病活性を有する縮合芳香族化合物を用いた治療法
JP2015145891A Pending JP2015227359A (ja) 2007-05-07 2015-07-23 抗糖尿病活性を有する縮合芳香族化合物を用いた治療法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014002247A Pending JP2014088424A (ja) 2007-05-07 2014-01-09 抗糖尿病活性を有する縮合芳香族化合物を用いた治療法
JP2015145891A Pending JP2015227359A (ja) 2007-05-07 2015-07-23 抗糖尿病活性を有する縮合芳香族化合物を用いた治療法

Country Status (6)

Country Link
US (1) US8338458B2 (enExample)
EP (1) EP2155187B1 (enExample)
JP (3) JP2010526807A (enExample)
AU (1) AU2008248186B2 (enExample)
CA (1) CA2688187C (enExample)
WO (1) WO2008137105A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013068486A1 (en) 2011-11-08 2013-05-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of male infertility
EP2964221B1 (en) 2013-03-04 2017-12-06 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2014134774A1 (en) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2014134772A1 (en) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2014134776A1 (en) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
SG11201809751XA (en) 2016-05-26 2018-12-28 Zeno Royalties & Milestones Llc Egfr inhibitor compounds
AU2019209470A1 (en) 2018-01-16 2020-08-13 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2019143730A1 (en) 2018-01-16 2019-07-25 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
BR112021008516A2 (pt) 2018-11-01 2021-09-14 Syros Pharmaceuticals, Inc. Inibidores de quinase 7 dependente de ciclina (cdk 7)
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
PE20240687A1 (es) 2020-12-30 2024-04-10 Tyra Biosciences Inc Compuestos de indazol como inhibidores de cinasas

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002503203A (ja) 1996-02-02 2002-01-29 メルク エンド カンパニー インコーポレーテッド 抗糖尿病薬及び抗肥満症薬としての複素環誘導体
AU1856997A (en) 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
WO2001030343A1 (en) 1999-10-22 2001-05-03 Merck & Co., Inc. Pharmaceuticals for treating obesity
EP1259494A4 (en) 2000-02-18 2004-09-15 Merck & Co Inc ARYLOXYACETIC ACIDS FOR DIABETES AND LIPID DISORDERS
JP2001354671A (ja) 2000-04-14 2001-12-25 Nippon Chemiphar Co Ltd ペルオキシソーム増殖剤応答性受容体δの活性化剤
WO2002008188A1 (en) 2000-07-25 2002-01-31 Merck & Co., Inc. N-substituted indoles useful in the treatment of diabetes
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
BR0206831A (pt) 2001-02-02 2004-07-06 Takeda Chemical Industries Ltd Composto, cristal, agente farmacêutico, agentes para profilaxia ou tratamento de diabetes, de complicações diabéticas, de tolerância prejudicada à glucose e de obesidade, inibidor de peptidase, uso de um composto, e, método de produção de um composto
US7091230B2 (en) 2001-02-09 2006-08-15 Merck & Co., Inc. 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
EP1385508B1 (en) 2001-03-27 2008-05-21 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US6573287B2 (en) 2001-04-12 2003-06-03 Bristo-Myers Squibb Company 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
FR2824825B1 (fr) 2001-05-15 2005-05-06 Servier Lab Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US7098239B2 (en) 2001-06-20 2006-08-29 Merck & Co., Inc Dipeptidyl peptidase inhibitors for the treatment of diabetes
CA2450475A1 (en) 2001-06-20 2003-01-03 Linda Brockunier Dipeptidyl peptidase inhibitors for the treatment of diabetes
GB0115517D0 (en) 2001-06-25 2001-08-15 Ferring Bv Novel antidiabetic agents
CA2419888A1 (en) 2001-06-27 2003-01-09 Probiodrug Ag Peptide structures useful for competitive modulation of dipeptidyl peptidase iv catalysis
DE60222667T2 (de) 2001-06-27 2008-07-17 Smithkline Beecham Corp. Fluorpyrrolidine als dipeptidylpeptidaseinhibitoren
US7196201B2 (en) 2001-06-27 2007-03-27 Smithkline Beecham Corporation Pyrrolidines as dipeptidyl peptidase inhibitors
US7183290B2 (en) 2001-06-27 2007-02-27 Smithkline Beecham Corporation Fluoropyrrolidines as dipeptidyl peptidase inhibitors
DE60225556D1 (de) 2001-07-03 2008-04-24 Novo Nordisk As Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
ATE319449T1 (de) * 2001-12-21 2006-03-15 Smithkline Beecham Corp Dosierschema für ppar-gamma-aktivatoren
ATE373660T1 (de) 2002-03-25 2007-10-15 Merck & Co Inc Heterocyclische beta-aminoverbindungen als inhibitoren der dipeptidylpeptidase zur behandlung bzw. prävention von diabetes
WO2004007468A1 (en) 2002-07-15 2004-01-22 Merck & Co., Inc. Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes
AU2003254852A1 (en) 2002-08-08 2004-02-25 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds as peptidase inhibitors
DK1537078T3 (da) 2002-08-29 2010-08-02 Merck Sharp & Dohme Indoler med anti-diabetisk aktivitet
CA2495915A1 (en) 2002-08-29 2004-03-11 Merck & Co., Inc. Indoles having anti-diabetic activity
US7390809B2 (en) 2002-10-07 2008-06-24 Merck & Co., Inc. Beta-amino heterocyclic dipeptidyl peptidase inhibitors for diabetes
RU2301803C2 (ru) 2002-10-18 2007-06-27 Мерк Энд Ко., Инк. Производные гексагидродиазепинона, фармацевтическая композиция, их содержащая, и применение для получения лекарственного средства для лечения инсулиннезависимого диабета
CA2504735C (en) 2002-11-07 2009-06-23 Merck & Co., Inc. Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
CA2562082C (en) 2004-04-13 2013-06-25 Merck & Co., Inc. Cetp inhibitors for the treatment and prevention of atherosclerosis
DOP2005000123A (es) 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
WO2006033891A2 (en) 2004-09-16 2006-03-30 Merck & Co., Inc. Compounds for the treatment of dyslipidemia and other lipid disorders
US9040558B2 (en) * 2004-12-31 2015-05-26 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
DOP2006000018A (es) 2005-01-28 2006-07-15 Lilly Co Eli Formulaciones y regimen de dosificación para moduladores alfa de ppar
CN102584754B (zh) * 2005-03-04 2016-02-03 默沙东公司 具有抗糖尿病活性的稠合芳香化合物
JP2008533033A (ja) 2005-03-10 2008-08-21 メルク エンド カムパニー インコーポレーテッド 抗糖尿病化合物の新規な結晶形態

Similar Documents

Publication Publication Date Title
JP2010526807A5 (enExample)
JP2005508318A5 (enExample)
JP2018535963A5 (enExample)
TWI376370B (en) Compounds for inflammation and immune-related uses
JP2007514756A5 (enExample)
JP6409004B2 (ja) ソルチリン阻害剤としてのｎ置換された５置換フタルアミド酸
JP2019034943A5 (enExample)
JP2018536648A5 (enExample)
JP2009533410A5 (enExample)
JP2009542717A5 (enExample)
RU2017131875A (ru) Трехъядерные соединения и их применение в медицине
CN110944997A (zh) Fxr受体激动剂
CN101090724A (zh) 用于抑制人硬脂酰CoA去饱和酶的吡啶衍生物
WO2009114994A1 (zh) 哒嗪酮类化合物在制备抗肿瘤药物中的用途
TW200403210A (en) Benzamide derivatives
JP2013500314A5 (enExample)
JP2010529203A5 (enExample)
JP2019524883A5 (enExample)
JP2009531390A5 (enExample)
CA2798610A1 (en) Bicyclic heteroaryl compounds as gpr119 modulators
JP2018516963A5 (enExample)
JP2017538773A5 (enExample)
JP2016508506A5 (enExample)
JP2010516701A5 (enExample)
JPWO2009038112A1 (ja) Ｎｐｙｙ５受容体拮抗剤を含有する固形製剤